Premium
FDG‐2‐nitroimidazole: A new potential hypoxia tracer using glucose transport
Author(s) -
Patt M.,
Sorger D.,
Scheunemann M.,
Stöcklin G.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401137
Subject(s) - chemistry , nitroimidazole , hexokinase , in vivo , tracer , in vitro , hypoxia (environmental) , adduct , glucose transporter , glucose uptake , radiochemistry , biochemistry , oxygen , metabolism , glycolysis , organic chemistry , medicine , microbiology and biotechnology , physics , nuclear physics , insulin , biology
A promising new radiotracer for the detection of hypoxic tissue in vivo with PET has been synthesized in good yields starting from tetra‐O‐acetyl‐2‐[ 18 F]FDG available in high amounts in 2‐[ 18 F]FDG synthesis. The new tracer representing an adduct of 2‐nitroimidazole and 2‐[ 18 F]FDG is not phosphorylated in vitro by hexokinase thus excluding a second non‐hypoxia dependent trapping mechanism. Furthermore it has been shown to interfere with glucose transport proteins since it inhibits the cellular uptake of [ 18 F]FDG in a concentration‐dependent manner.